Emcure Pharmaceuticals Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6kcsnm91j1tcp31dwxx6tkhq.pdf

Key Takeaways


Domestic Business: The Core Problem

Satish Mehta: "Yes, we are doing exceedingly well in the international market but for me, the main objective is to put the domestic market on track and we need to grow more than the industry growth and that is my very immediate goal and objective for which I am giving my undiluted attention to ensure that the domestic growth also picks up in the next few months."

International: The Growth Engine


Pipeline & New Bets

Satish Mehta: "The Economist is projecting sales of something like a $100 billion for this particular product along with Eli Lily's Mounjaro. So it is anyone's guess."

Margins: Compressed but with a Multi-Year Promise

Vikas Thapar: "we believe that we should definitely be getting about a 300 to 400 basis points improvement in the margin profile over that time horizon. That will be the endeavour."

Balance Sheet & Capital Allocation

Satish Mehta: "Before listing, we had 20-25 equity holders and now we know the family is more than 140,000 and that puts enormous amount of responsibility on me as CEO, and all of us at Emcure are acutely conscious of our responsibility."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic growth pickupGrow faster than industry; immediate goal to get domestic growth to pick upNext few months
Cardiac segment improvementImprovement from current quarter, though may not fully normalizeQ4 FY25 onwards
Domestic growth targetIn line with industry plus 50–100 bpsOngoing
Recombinant Asparaginase approvalDCGI clearanceNext 6 months
Semaglutide India launchFirst wave at loss of exclusivityMarch 2026
Europe growth returnHigh single-digit growthFY26
Canada growth profileMid-teens growthOngoing
Derma new launches (Emcutix)In-house and partner productsStarting FY26
Margin improvement300–400 bps improvement in margin profile3–4 year horizon
Net cash balance sheetSubject to no M&ABy March 2026
R&D spendMaintain at 4–5% of revenueOngoing

Key Metrics

MetricQ3 FY25
Revenue from operations₹1,963 cr, +18% YoY
Domestic revenue₹888 cr, +12% YoY
International revenue₹1,075 cr, +23% YoY
Canada revenue₹352 cr, +34% YoY
Emerging markets revenue₹365 cr, +40% YoY
Europe revenue₹358 cr, +2% YoY
Gross margin60.1%, vs 62.7% in Q3 FY24
EBITDA (excl. other income)₹362 cr, +23% YoY
EBITDA margin18.4%, up YoY
Adjusted PAT (excl. one-time tax)₹171 cr, +43% YoY
Reported PAT₹156 cr
Net debt₹600 cr, down from ₹705 cr in Q2 FY25
Working capital days96 days, stable
Domestic organic growth ex-FCM4% (per an analyst's math)
PCPM6.1, vs 5.6 in Q3 FY24
R&D spend4%–5% of revenue